Antibody titres decline 3-month post-vaccination with BNT162b2
Top Cited Papers
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Emerging Microbes & Infections
- Vol. 10 (1), 1495-1498
- https://doi.org/10.1080/22221751.2021.1953403
Abstract
Several studies reported on the humoral response in subjects having received the BNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months post-vaccination are currently lacking and are important to drive the future vaccination strategy. The CRO-VAX HCP study is an ongoing multicenter, prospective and interventional study designed to assess the antibody response in a population of healthcare professionals who had received two doses of the BNT162b2 mRNA COVID-19 vaccine. Two-hundred individuals underwent a blood drawn within 2 days before the first vaccine dose. One-hundred and forty-two persons (71%) were categorized as seronegative at baseline while 58 (29%) were seropositive. Samples were then collected after 14, 28, 42, 56, and 90 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points. Using a one-compartment kinetics model, the time to maximum concentration was estimated at 36 ± 3 days after the first dose and the estimated half-life of antibodies was 55 days (95% CI: 37-107 days) in seronegative participants. In seropositive participants, the time to maximum concentration was estimated at 24 ± 4 days and the estimated half-life was 80 days (95% CI: 46-303 days). The antibody response was higher in seropositive compared to seronegative participants. In both seropositive and seronegative subjects, a significant antibody decline was observed at 3 months compared to the peak response. Nevertheless, the humoral response remained robust in all participants.Keywords
This publication has 14 references indexed in Scilit:
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19The New England Journal of Medicine, 2021
- COVID-19 Vaccines vs Variants—Determining How Much Immunity Is EnoughJAMA, 2021
- Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2Nature Medicine, 2021
- Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workersJournal of Infection, 2021
- Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after InfectionMicroorganisms, 2021
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infectionScience, 2021
- Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal studyClinical Microbiology & Infection, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based StudyJournal of Clinical Medicine, 2020
- Clinical Performance of the Elecsys Electrochemiluminescent Immunoassay for the Detection of SARS-CoV-2 Total AntibodiesClinical Chemistry, 2020